Completed PHASE3 INTERVENTIONAL 1-arm NCT01660841

Safety and Efficacy of Gadobutrol 1.0 Molar in Japanese Subjects for CNS Imaging

A Multicenter, Open-label, Phase III Study to Determine the Safety and Efficacy of Gadobutrol 1.0 Molar in Japanese Subjects Referred for Contrast-enhanced MRI of the Central Nervous System (CNS)

Sponsor: Bayer

Conditions Magnetic Resonance Imaging

Interventions Gadobutrol (Gadovist, BAY86-4875)

Updated 6 times since 2017 Last updated: Sep 30, 2014 Started: Sep 30, 2012 Primary completion: Aug 31, 2013 Completion: Aug 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01660841, this PHASE3 trial focuses on Magnetic Resonance Imaging and remains completed. Sponsored by Bayer, it has been updated 6 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Sep 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer

Data source: Bayer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Daitō, Japan , Fujisawa, Japan , Fukuoka, Japan , Fukuyama, Japan , Funabashi, Japan , Kawasaki, Japan , Kishiwada, Japan , Kitakyushu, Japan , Kobe, Japan , Nagoya, Japan and 3 more locations